Senti Biosciences Holdings, Inc.
SNTI
SNTI
Nasdaq
Health Technology
Biotechnology
0.39
USD-0.0051
-1.30%
Closed: 08-26 20:00 (UTC+0)
0.38
USD-0.0063
-1.63%
After Hours: 08-27 00:00 (UTC+0)
SNTI Key Statistics
High
0.40
Open
0.39
Volume
74.48K
Low
0.37
Prev. Close
0.39
Trading Value
28.88K
52-Week High
2.88
Relative Volume
0.35
Amplitude (%)
7.61%
52-Week Low
0.33
Turnover Rate
0.24%
Market Cap
12.03M
P/E Ratio (TTM)
--
P/E Ratio (Annual)
--
P/B Ratio
-3.57
P/S Ratio
220.84
Earnings Per Share (EPS)
-1.765
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
31.14M
Currency Unit
USD
SNTI Price Performance
7 day
30 day
90 day
180 day
Year to date
1 Year
SNTI Money Flow Distribution
SNTI Daily Short Sale Volume
SNTI Short Interest History
SNTI Stock Snapshot
As of 2026-08-27, the Senti Biosciences Holdings, Inc. (SNTI) stock price today is 0.3864. Based on this price, the company has a market capitalization of $12.03M, with a P/E ratio of --.
On 2026-08-27, SNTI traded between 0.37 and 0.40. Today’s stock price is 4.43% above the daily low and 3.40% below the daily high, placing SNTI near the middle of its most recent trading range.
Trading volume currently stands at 74.48K, compared with an average daily volume of 213.02K. This suggests that trading activity is significantly below its usual level than usual.
Over the past year, Senti Biosciences Holdings, Inc. shares have traded between 0.33 and 2.88. At today’s price, SNTI is 17.09% above its 52-week low and 86.58% below its 52-week high.
SNTI Related News
About SNTI
Company Name
Senti Biosciences Holdings, Inc.
Sector
Health Technology
Industry
Biotechnology
Exchanges
Nasdaq
Number of Employees
39
Lot Size
100
Official Website
Currency Unit
USD
Senti Biosciences Holdings, Inc. (SNTI) is a clinical-stage biotechnology company developing gene-circuit-engineered cell and gene therapies. Its SENTI platform is designed to control therapeutic activity in response to biological signals. Lead candidate SENTI-202 is an off-the-shelf logic-gated CAR-NK therapy in a Phase 1 trial in the United States and Australia for relapsed or refractory blood cancers including acute myeloid leukemia.
Related Stocks
SNTI FAQ
© 2026 CoinGlass, all rights reserved
